Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure: A Multicenter, Open-Label, Blinded-Outcome Randomized Controlled Trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 41706075.
- Also identified by DOI 10.1016/j.jacc.2026.01.014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
It is challenging to achieve sustained blood pressure (BP) lowering by traditional lifestyle guidance including exercise. We aimed to evaluate the short-term effects of baduanjin on ambulatory BP with monitoring and long-term effects without monitoring among individuals with high-normal BP. We conducted a multicenter, open-label, blinded-outcome randomized controlled trial at 7 communities. Participants aged ≥40 years with systolic blood pressure (SBP) 130 to 139 mm Hg and/or diastolic BP 85 to 89 mm Hg were randomly assigned in a 2:1:1 ratio to the baduanjin, self-directed exercise alone, or brisk walking arms for a 52-week intervention. The primary outcomes were the changes in 24-hour SBP from baseline to 12 and 52 weeks. Intention-to-treat analyses of primary outcomes followed a hierarchical testing sequence: 1) superiority of baduanjin vs self-directed exercise alone at 12 weeks; 2) superiority of baduanjin vs self-directed exercise alone at 52 weeks; and 3) superiority of baduanjin vs brisk walking at 52 weeks. Among 216 eligible participants (mean age 57.3 years; 64.8% women), 108, 54, and 54 participants were randomly assigned to the baduanjin, self-directed exercise alone, and brisk walking arms, respectively. The baduanjin arm obtained a significantly greater reduction in 24-hour SBP compared with the self-directed exercise alone arm at 12 weeks (-3.1 mm Hg; 95% CI: -5.9 to -0.2 mm Hg; P = 0.036) and 52 weeks (-3.3 mm Hg; 95% CI: -6.3 to -0.3 mm Hg; P = 0.031). There was no significant difference between the baduanjin and brisk walking arms (-0.7 mm Hg; 95% CI: -3.9 to 2.6 mm Hg; P = 0.683) at 52 weeks. The effects were not heterogeneous across subgroups. No significant difference in adverse events was detected across 3 arms. Baduanjin lowered SBP after 3 months of intervention in individuals with high-normal BP, with sustained BP-lowering effect until 1 year without monitoring, and showed comparable efficacy to brisk walking. (Baduanjin Lowering Elevated Blood PreSsure Study [BLESS]; NCT05397535).